# Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

> **NCT00606645** · PHASE1 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma

## Interventions

- **BIOLOGICAL:** XmAb2513

## Key facts

- **NCT ID:** NCT00606645
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606645, "Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00606645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*